Примери за използване на Lenalidomide accord на Английски и техните преводи на Български
{-}
-
Colloquial
-
Official
-
Medicine
-
Ecclesiastic
-
Ecclesiastic
-
Computer
Lenalidomide Accord is a medicine used for the treatment of multiple myeloma,
Lenalidomide Accord 7.5 mg, Lenalidomide Accord 20 mg and Lenalidomide Accord 25 mg hard capsules.
This means that Lenalidomide Accord contains the same active substance
Lenalidomide Accord is available as capsules of various strengths to be taken by mouth.
For more information about using Lenalidomide Accord, see the package leaflet
Side effects reported with Lenalidomide Accord are carefully evaluated
The company that markets Lenalidomide Accord will provide a letter
Why is Lenalidomide Accord authorised in the EU?
Lenalidomide Accord 25 mg hard capsules:• The active substance is lenalidomide.
NAME OF THE MEDICINAL PRODUCT Lenalidomide Accord 10 mg hard capsules lenalidomide.
NAME OF THE MEDICINAL PRODUCT Lenalidomide Accord 25 mg hard capsules lenalidomide.
What Lenalidomide Accord is used for Lenalidomide Accord is used in adults for multiple myeloma.
Local country specific arrangements for a prescription for Lenalidomide Accord to be dispensed.
Lenalidomide Accord hard capsules are available in OPA AL PVC/Aluminium foil perforated unit dose blister.
Multiple myeloma- in patients who have had treatment before Lenalidomide Accord is taken together with an anti-inflammatory medicine called‘dexamethasone'.
Lenalidomide Accord 10 mg and Lenalidomide Accord 20 mg hard capsules Gelatin.
Lenalidomide Accord in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy.
Further information on Lenalidomide Accord can be found on the Agency's website:
Lenalidomide Accord as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation.
Lenalidomide Accord as combination therapy(see section 4.2)